Baidu
map

Crit Care Med:容量反应性的动态评估对临床治疗的指导作用到底如何?

2017-08-26 MedSci MedSci原创

目前,在靶向治疗的临床试验中已经开发和研究了容量反应性的动态测试。但是,这种方法对临床相关结局的影响仍然是未知的。近期,一项发表在杂志Crit Care Med上的研究进行了系统评价和荟萃分析,以评估与标准护理相比,容量反应性动态评估指导下的流体治疗是否能改善进入ICU的成年人的临床相关结果。研究者们检索了自开始到2016年12月MEDLINE、EMBASE、CENTRAL、clinicaltri

目前,在靶向治疗的临床试验中已经开发和研究了容量反应性的动态测试。但是,这种方法对临床相关结局的影响仍然是未知的。


近期,一项发表在杂志Crit Care Med上的研究进行了系统评价和荟萃分析,以评估与标准护理相比,容量反应性动态评估指导下的流体治疗是否能改善进入ICU的成年人的临床相关结果。

研究者们检索了自开始到2016年12月MEDLINE、EMBASE、CENTRAL、clinicaltrials.gov和国际临床试验注册平台的随机对照试验,会议记录和相关文章的参考。由两名评审员独立确定随机对照试验,比较入住ICU中的成人进行容量反应性的动态评估与标准急性容量复苏的护理。

两位评审员独立提取试验数据,包括人口特征、干预措施、临床结果和资金来源。此项研究的主要结果是最长随访时间的死亡率。次要结局是ICU和住院时间,机械通气时间和肾并发症发生的频率。使用Cochrane Collaboration的“偏见风险”工具对试验的内部有效性进行了一次评估。
最终,此项研究共包括了13项试验,招募了1652名患者。用于评估容量反应性的方法包括中风体积变化(九项试验),脉搏压力变化(一项试验),以及被动腿部抬高/流体挑战(三项试验)的中风体积变化。

在报告死亡率的12项试验中,与容量反应性动态评估相关的死亡风险比为0.59(95%CI,0.42-0.83;I = 0%;n = 1,586)。与容量反应性动态评估相关的死亡率绝对风险降低-2.9%(95%CI,-5.6%至-0.2%)。容量反应性的动态评估与ICU住院时间减少(加权平均差异-1.16 d(95%CI,-1.97至-0.36); I = 74%; n = 394,6项试验)以及机械通气减少相关(加权平均差异,-2.98小时[95%CI,-5.08至-0.89];I = 34%; n = 334,5项试验)。

此项研究表明:在需要进行急性容量复苏的重症监护成年患者中,以容量反应性评估为指导的目标导向治疗似乎与降低死亡率,ICU停留时间和机械通气持续时间有关。

原始出处:
Bednarczyk JM, Fridfinnson JA, et al. Incorporating Dynamic Assessment of Fluid Responsiveness Into Goal-Directed Therapy: A Systematic Review and Meta-Analysis. Crit Care Med. 2017 Sep;45(9):1538-1545. doi: 10.1097/CCM.0000000000002554.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2022795, encodeId=578f2022e9566, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun Jun 24 12:21:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239817, encodeId=664f23981eb6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98dd1959726, createdName=游手好闲, createdTime=Sat Sep 02 20:59:53 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525808, encodeId=cd26152580886, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Mon Aug 28 02:21:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607974, encodeId=2e36160e9745d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 28 02:21:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237407, encodeId=2a1923e40797, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Aug 26 15:26:21 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237354, encodeId=d50223e35445, content=好文章.值得学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Aug 26 11:51:37 CST 2017, time=2017-08-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2022795, encodeId=578f2022e9566, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun Jun 24 12:21:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239817, encodeId=664f23981eb6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98dd1959726, createdName=游手好闲, createdTime=Sat Sep 02 20:59:53 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525808, encodeId=cd26152580886, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Mon Aug 28 02:21:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607974, encodeId=2e36160e9745d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 28 02:21:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237407, encodeId=2a1923e40797, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Aug 26 15:26:21 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237354, encodeId=d50223e35445, content=好文章.值得学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Aug 26 11:51:37 CST 2017, time=2017-08-26, status=1, ipAttribution=)]
    2017-09-02 游手好闲

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2022795, encodeId=578f2022e9566, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun Jun 24 12:21:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239817, encodeId=664f23981eb6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98dd1959726, createdName=游手好闲, createdTime=Sat Sep 02 20:59:53 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525808, encodeId=cd26152580886, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Mon Aug 28 02:21:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607974, encodeId=2e36160e9745d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 28 02:21:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237407, encodeId=2a1923e40797, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Aug 26 15:26:21 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237354, encodeId=d50223e35445, content=好文章.值得学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Aug 26 11:51:37 CST 2017, time=2017-08-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2022795, encodeId=578f2022e9566, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun Jun 24 12:21:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239817, encodeId=664f23981eb6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98dd1959726, createdName=游手好闲, createdTime=Sat Sep 02 20:59:53 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525808, encodeId=cd26152580886, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Mon Aug 28 02:21:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607974, encodeId=2e36160e9745d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 28 02:21:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237407, encodeId=2a1923e40797, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Aug 26 15:26:21 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237354, encodeId=d50223e35445, content=好文章.值得学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Aug 26 11:51:37 CST 2017, time=2017-08-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2022795, encodeId=578f2022e9566, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun Jun 24 12:21:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239817, encodeId=664f23981eb6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98dd1959726, createdName=游手好闲, createdTime=Sat Sep 02 20:59:53 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525808, encodeId=cd26152580886, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Mon Aug 28 02:21:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607974, encodeId=2e36160e9745d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 28 02:21:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237407, encodeId=2a1923e40797, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Aug 26 15:26:21 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237354, encodeId=d50223e35445, content=好文章.值得学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Aug 26 11:51:37 CST 2017, time=2017-08-26, status=1, ipAttribution=)]
    2017-08-26 Y—xianghai

    学习了新知识

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2022795, encodeId=578f2022e9566, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun Jun 24 12:21:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239817, encodeId=664f23981eb6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98dd1959726, createdName=游手好闲, createdTime=Sat Sep 02 20:59:53 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525808, encodeId=cd26152580886, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Mon Aug 28 02:21:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607974, encodeId=2e36160e9745d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 28 02:21:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237407, encodeId=2a1923e40797, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Aug 26 15:26:21 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237354, encodeId=d50223e35445, content=好文章.值得学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Aug 26 11:51:37 CST 2017, time=2017-08-26, status=1, ipAttribution=)]
    2017-08-26 1e0f8808m18(暂无匿称)

    好文章.值得学习.

    0

Baidu
map
Baidu
map
Baidu
map